Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ingevity Corporation (NYSE: NGVT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered context to help interpret them. Ingevity is a specialty materials and chemical manufacturer organized into three segments—Performance Materials, Advanced Polymer Technologies and Performance Chemicals—and its filings document how these businesses are managed, restructured and financed over time.
Investors can use Ingevity’s Form 10-K annual reports and Form 10-Q quarterly reports to review segment information, including sales and EBITDA for Performance Materials (activated carbon), Advanced Polymer Technologies (caprolactone polymers) and Performance Chemicals (specialty chemicals and pavement or road technologies). These reports also describe the applications for Ingevity’s products, such as adhesives, agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings, lubricants, oil drilling and automotive components.
Ingevity’s Form 8-K current reports are particularly important for tracking material events that affect NGVT stock. Recent 8-K filings detail the asset purchase agreement and subsequent amendment with Mainstream Pine Products, LLC for the sale of the North Charleston crude tall oil refinery and the majority of the Industrial Specialties product line, the classification of those operations as discontinued, and the completion of the transaction. Other 8-Ks describe leadership transitions in finance and business segments, the completion of a portfolio review and the decision to explore strategic alternatives for the Advanced Polymer Technologies segment and the Performance Chemicals Road Markings business, as well as preliminary earnings announcements.
On this page, AI-generated summaries highlight the key points of each filing, helping users quickly understand what a lengthy 8-K, 10-Q or 10-K means for Ingevity’s portfolio, margins, cash flow and capital allocation. Filings related to stock repurchases, strategic divestitures and executive changes are surfaced so that investors can monitor how the company is reshaping its specialty chemicals and materials portfolio. Users can also review exhibits referenced in 8-Ks, such as asset purchase agreements and recast financial information, to gain deeper insight into the structure and impact of major transactions.
Ingevity Corporation has agreed to sell substantially all assets of its industrial specialties product line (excluding lignin dispersant, alternative fatty acid based products, road technologies and certain other businesses) and its North Charleston, South Carolina crude tall oil refinery to Mainstream Pine Products, LLC under an Asset Purchase Agreement.
The Transaction provides for a purchase price of $110 million in cash, subject to customary working capital adjustments, plus up to an additional $19 million in contingent consideration based on the Businesses’ highest EBITDA over any 12‑month period within 36 months after closing. Closing is expected by early Q1 2026, subject to regulatory and contractual conditions, including absence of a Material Adverse Effect and completion of title and survey work.
The Agreement includes mutual termination rights, a $5 million termination fee for certain material breaches, a $7.5 million fee if Ingevity pursues an Alternative Transaction in violation of a “no shop” covenant, and a $520,000 diligence fee payable by Ingevity in most other termination scenarios. At closing, the parties plan to enter long‑term ground lease and reciprocal plant operating agreements (each with an initial 20‑year term and renewal options), transition services, intellectual property, restrictive covenant and environmental indemnity agreements that will govern ongoing collaboration around the refinery and nearby plant operations.
Phillip J. Platt, SVP, Finance & CAO of Ingevity Corp (NGVT), reported an equity transaction tied to vested restricted stock units. On 08/11/2025 the company withheld 1,444 shares to satisfy tax-withholding obligations related to 2024 RSUs that vested on that date. The transaction is coded F and shows a withholding value of $52.20 per share. After the withholding, Mr. Platt directly beneficially owned 28,243 shares.
This was a routine tax-withholding action for vested equity rather than an open-market sale; the form was submitted by one reporting person and executed under a power of attorney.
Ingevity Corporation (NGVT) Form 144 reports that insider Stuart E. Woodcock Jr. intends to sell 3,700 common shares on 08/11/2025 through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $194,662.55. The filing lists the securities as restricted stock that vested under a registered plan with acquisition dates of 02/27/2017, 02/27/2018 and 02/26/2020, and records a recent separate sale on 08/05/2025 of 6,720 shares for $323,904.00. Outstanding shares are shown as 36,466,285, so the planned sale represents a very small fraction of total common stock.
The notice includes the seller’s representation that they do not possess undisclosed material adverse information. The document otherwise provides routine Rule 144 disclosure details: broker, share counts, acquisition type, and prior recent sales by the same person.
Ingevity Corporation (NGVT) – Form 4 Insider Filing: Senior Vice President, General Counsel & Secretary Ryan C. Fisher reported a transaction dated 7 July 2025. The filing shows a Code F transaction in which 169 shares of common stock were withheld by the company at a price of $45.34 per share to cover tax obligations arising from the vesting of 2024 restricted stock units (RSUs). After the withholding, Fisher’s direct ownership stands at 14,758 NGVT shares. No derivative securities activity was reported, and there were no open-market purchases or sales.
Because Code F transactions are non-discretionary, cashless, and executed solely for tax-withholding, they typically carry limited market signaling value. The ownership reduction equals roughly -1.1% of Fisher’s previously held shares, a de-minimis change that is unlikely to materially affect investor perception of insider sentiment or the company’s share supply.
Ingevity Corporation (NGVT) Form 4 filing: Director Francis David Segal reported the acquisition of 507 common shares on 07/01/2025 at an implied price of $44.40 per share. The shares were received through the vesting of deferred stock units (DSUs) elected in lieu of quarterly director fees under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following the transaction, Segal’s direct beneficial ownership increased to 5,241 shares. No derivative securities were involved, and the transaction was coded “A” (acquisition) rather than an open-market purchase or sale. Because DSUs settle only after board service ends, the filing signals continued equity alignment but does not represent immediate cash investment.
Ingevity Corporation (NYSE: NGVT) filed a Form 8-K dated 1 July 2025 announcing the departure of S. Edward Woodcock, Executive Vice President and President of the Performance Materials segment (Item 5.02). The separation is effective the same day and a search for his successor has begun.
The company and Mr. Woodcock executed a Letter Agreement that mirrors provisions in his 2017 Severance and Change of Control Agreement. Key cash benefits include:
- A lump-sum payment within 30 days for accrued salary, prorated 2025 annual incentive, and unused vacation.
- Severance equal to one year of current base salary plus 2025 target bonus, payable monthly over 12 months.
- An additional $500,000 lump-sum tied to an October 2024 incentive award.
All consideration is conditioned on customary release of claims and ongoing covenant compliance (confidentiality, non-disparagement, non-competition, non-solicitation). The full Letter Agreement will be filed with the company’s Q2-25 10-Q.
Under Item 7.01, Ingevity furnished (but did not file) a press release (Exhibit 99.1) announcing the leadership change. No financial statements or earnings data were included.